Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Suite 1335, Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA.
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 13th floor, Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA.
Hematol Oncol Clin North Am. 2024 Oct;38(5):1027-1043. doi: 10.1016/j.hoc.2024.05.008. Epub 2024 Jun 5.
Metastasis to the brain is a frequent complication of advanced melanoma. Historically, patients with melanoma brain metastasis (MBM) have had dismal outcomes, but outcomes have improved with the development of more effective treatments, including stereotactic radiosurgery and effective immune and targeted therapies. Despite these advances, MBM remains a leading cause of death from this disease, and many therapies show decreased efficacy against these tumors compared with extracranial metastases. This differential efficacy may be because of recently revealed unique molecular and immune features of MBMs-which may also provide rational new therapeutic strategies.
脑转移是晚期黑色素瘤的常见并发症。历史上,黑色素瘤脑转移(MBM)患者的预后较差,但随着更有效的治疗方法的发展,包括立体定向放射外科和有效的免疫和靶向治疗,预后有所改善。尽管取得了这些进展,但 MBM 仍然是导致这种疾病死亡的主要原因,而且与颅外转移相比,许多治疗方法对这些肿瘤的疗效降低。这种疗效差异可能是由于最近发现的 MBM 的独特分子和免疫特征所致——这也可能为新的合理治疗策略提供依据。